adalimumab-aaty (Yuflyma) vs adalimumab-atto (Amjevita)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-aaty (Yuflyma)

Marketed by Celltrion

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT03789292 · Phase 3 · completed

This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).

Reported efficacy

American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)

Result source: NCT03789292

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01970475 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)

Result source: NCT01970475

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aaty (Yuflyma)adalimumab-atto (Amjevita)
ACR2082.7% vs 82.7%vs Humirawk 24 · n 324NCT0378929274.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
ACR50—Not reported49.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475
ACR70—Not reported26% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-aaty (Yuflyma)
82.7% vs 82.7%vs Humirawk 24 · n 324NCT03789292
adalimumab-atto (Amjevita)
74.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475

ACR50

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-atto (Amjevita)
49.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475

ACR70

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-atto (Amjevita)
26% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475

DAS28-CRP remission

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-atto (Amjevita)
—Not reported

HAQ-DI, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-atto (Amjevita)
—Not reported

Modified Sharp score, change

adalimumab-aaty (Yuflyma)
—Not reported
adalimumab-atto (Amjevita)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. adalimumab-aaty (Yuflyma): 5 of 5 rows · adalimumab-atto (Amjevita): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-aaty (Yuflyma)adalimumab-atto (Amjevita)
DAS28-CRP
absolute change · score
-2.738 vs -2.734 Humira score @ 24wka,b
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.32 vs -2.32 Adalimumab score @ 24wka,b
NCT01970475 · Phase 3
Dropout rate
6.5%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
8%c
NCT01970475 · Phase 3
Discontinued due to AEs
2.2%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
2.7%c
NCT01970475 · Phase 3
Serious AEs
—CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.7%Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
2%Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.3%Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.8%c
NCT01970475 · Phase 3
Most frequent reported AEs
upper respiratory tract infection 5.6%
nasopharyngitis 5.2%
injection site reaction 4.9%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
neutropenia 5%
upper respiratory tract infection 3.3%
urinary tract infection 3%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
neutropenia 5.3%
alanine aminotransferase increased 4.6%
leukopenia 4.6%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
c
nasopharyngitis 6.4%
NCT01970475 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-atto (Amjevita)

ACR50 49.2% (n=244) vs 52% (n=252) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3
ACR70 26% (n=246) vs 22.9% (n=253) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · adalimumab-atto (Amjevita)'s landscape